Cel Since 2014, the revolution of immuno-oncology gives unprecedented hope for cure to cancer patients thanks to immunotherapies such as anti-PD(L)-1. However around 80% patients still don’t respond to anti-PD(L)-1. Several barriers are still to be overcome to sustain the path of a novel paradigm responding both unmet therapeutic needs and health economy sustainability; cancer being estimated as a leading cause of deaths in Europe (350’000 deaths in 2012– Globocan) corresponding to an economical burden of €126BN in total costsPDC*line Pharma develops a ground-breaking therapeutic vaccine platform using an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line); potentially doubling the response rate to anti-PD(L)-1 without additional toxicity, eliminating complex and costly process usually required by cell therapies.Our innovation project is aiming to establish the clinical proof of concept that PDC*lung, our leading candidate for lung cancer can induce strong anti-tumour immunity in patients. Lung cancer is of high priority for Europe since 1.9 million people are affected worldwide of which 340 000 in Europe (Globocan, 2012). It also represents an attractive market segment opportunity for PDC*line Pharma with an expected market growth of 4% per year: $6.1BN in 2013 to $8.6BN in 2023 worldwide (IMS, 2015). Dziedzina nauki medical and health sciencesclinical medicineoncologylung cancersocial sciencespolitical sciencespolitical transitionsrevolutionsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicineimmunologyimmunotherapymedical and health sciencesmedical biotechnologycells technologies Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator PDC LINE PHARMA Wkład UE netto € 50 000,00 Adres C/O GATE1, PETITE HALLE 31 RUE GUSTAVE EIFFEL 38000 GRENOBLE Francja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Auvergne-Rhône-Alpes Rhône-Alpes Isère Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00